Dose the first patient in the SUNRISE clinical trial
Delivered after the deadline (63 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- 2 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Early 2021 – First patient to be dosed”
What we found
Evidence strength A What the grades mean
The company committed to dosing the first patient in early 2021, but the first patient was not dosed until June 2, 2021.
-
A LogicBio Therapeutics, Inc. 10-Q filed 2021-08-09
“On June 2, 2021, the Company announced that the first patient was dosed with LB-001 in its SUNRISE clinical trial.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First patient dosed in SUNRISE trial
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory, Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LogicBio Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C664106-021905 · Corrections policy